Nanodelivery Systems Targeting Epidermal Growth Factor Receptors for Glioma Management.

ABSTRACT: A paradigm shift in treating the most aggressive and malignant form of glioma is continuously evolving; however, these strategies do not provide a better life and survival index. Currently, neurosurgical debulking, radiotherapy, and chemotherapy are the treatment options available for glioma, but these are non-specific in action. Patients invariably develop resistance to these therapies, leading to recurrence and death. Receptor Tyrosine Kinases (RTKs) are among the most common cell surface proteins in glioma and play a significant role in malignant progression; thus, these are currently being explored as therapeutic targets. RTKs belong to the family of cell surface receptors that are activated by ligands which in turn activates two major downstream signaling pathways via Rapidly Accelera

SUBMITTER: Paranthaman S 

PROVIDER: S-EPMC7763629 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature